News Quantified

HELP – cybin inc. (US:NASDAQ)

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

2/10

07:56 am

help

Low

Helus Pharma appoints Michael Cola as CEO [Seeking Alpha]

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

Cybin (NASDAQ:HELP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $22.00 price target on the stock.

Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}